Sharp Therapeutics Corp.
SHRX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 28.25% | -- | -- | -- | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 24.37% | -- | -- | -- | |
| Operating Income | -24.37% | -- | -- | -- | |
| Income Before Tax | 0.87% | -- | -- | -- | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | 0.87% | -- | -- | -- | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 0.87% | -- | -- | -- | |
| EBIT | -24.37% | -- | -- | -- | |
| EBITDA | -28.49% | -- | -- | -- | |
| EPS Basic | -91.94% | -- | -- | -- | |
| Normalized Basic EPS | -70.42% | -- | -- | -- | |
| EPS Diluted | -91.94% | -- | -- | -- | |
| Normalized Diluted EPS | -70.42% | -- | -- | -- | |
| Average Basic Shares Outstanding | 107.12% | -- | -- | -- | |
| Average Diluted Shares Outstanding | 107.12% | -- | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |